ArticleJournal of gastroenterology2026
Novel driver gene FIRRM regulates the cell cycle for promoting tumor growth in hepatocellular carcinoma.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbnormalities in the cell cycle are fundamental mechanisms underlying tumor progression in hepatocellular carcinoma (HCC). Therapeutic strategies targeting mutations or abnormal activation of genes and pathways associated with cell cycle control are under development. However, the efficacy of cell cycle-targeted therapies is currently limited; therefore, identifying additional biomarkers and therapeutic targets is necessary.
methodsCopy number variation was analyzed using The Cancer Genome Atlas dataset for identifying FIRRM (fidgetin-like 1-interacting regulator of recombination and mitosis) as a potential driver of HCC development, and evaluating its clinical significance. Furthermore, the biological significance of FIRRM in HCC was validated using in vitro and in vivo studies involving FIRRM-knockout HCC cell lines.
resultsFIRRM is located on amplified chromosome 1q and exhibits elevated expression in tumor cells. It was identified as an independent poor prognostic factor in patients with HCC, and immunohistochemical staining revealed that it was primarily localized in the cytoplasm and membranes of HCC cells. FIRRM knockout suppressed HCC cell proliferation, reduced polo-like kinase 1 (PLK1) phosphorylation, and inhibited mitotic progression and the G2-to-M transition of the cell cycle. Furthermore, FIRRM knockout inhibited tumor proliferation in vivo.
conclusionFIRRM was identified as a novel driver gene in HCC, which accelerated tumor proliferation through PLK1-mediated mitotic progression and promotion of the G2/M transition. These findings suggest that FIRRM is a promising target for HCC therapy.
Indexed as
Identifiers
42007975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.